Different concentrations of nivolumab reduce PD-1 expression but not tumour growth in an EMT6 mouse model
Introduction: The interaction between the T cell immune checkpoint proteins, the programmed death-1 (PD-1) receptor, and its ligand PD-L1 plays a crucial role in T cell suppression and the evasion of cancer cells from immune detection, thereby promoting tumour growth. Nivolumab, a PD-1 inhibitor, di...
| الحاوية / القاعدة: | Biomedical Research and Therapy |
|---|---|
| المؤلف الرئيسي: | |
| التنسيق: | مقال |
| اللغة: | English |
| منشور في: |
BiomedPress
2024
|
| الوصول للمادة أونلاين: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85219117249&doi=10.15419%2fbmrat.v11i2.864&partnerID=40&md5=97a6ca65123b9e18dce0e02386748aa6 |